Loading...
•
Dec 31, 2019
Cencora Q1 2020 Earnings Report
Revenue increased by 5.4% and adjusted EPS increased by 10.0%.
Key Takeaways
AmerisourceBergen reported a strong first quarter in fiscal year 2020, with revenue reaching $47.9 billion, a 5.4% increase year-over-year. Adjusted diluted EPS grew by 10.0% to $1.76. The company has raised its adjusted diluted EPS guidance range for fiscal year 2020 to $7.55 to $7.80. The Board of Directors also increased the quarterly dividend rate by 5% to $0.42 per share.
Revenue increased by 5.4% to $47.9 billion.
GAAP diluted EPS was $0.90, compared to $1.84 in the prior year quarter.
Adjusted diluted EPS increased by 10.0% to $1.76.
Adjusted diluted EPS guidance range raised to $7.55 to $7.80 for fiscal 2020.
Cencora
Cencora
Forward Guidance
AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company’s strong performance, opportunistic share repurchases and the exit of our PharMEDium business. The Company now expects adjusted Diluted EPS to be in the range of $7.55 to $7.80, adjusted operating income growth in the mid-single digit percent range and Weighted average diluted shares are now expected to be approximately 208 million.
Positive Outlook
- Adjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.
- Adjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range
- Pharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from the low- to mid-single digit percent range
- Weighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of between 209 million to 210 million for the fiscal year.
- All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.